Philadelphia, PA – Neuronetics, Inc. recently held its Q4 2023 Earnings Conference Call on March 5th at 8:30 AM.

During the call, Neuronetics executives highlighted the company’s financial and operational achievements, discussing forward-looking statements and key strategic initiatives. President and CEO, Keith Sullivan, along with CFO Steve Furlong, provided an overview of the company’s performance in 2023, emphasizing key milestones and record quarters.

One notable highlight was the company’s focus on driving Treatment Session utilization, which led to a solid fourth quarter with over 20% year-over-year growth in utilization within the local consumable customer segment. Total revenue reached $20.3 million, marking a 12% increase over the previous year.

The NeuroStar Summit, an educational platform showcasing the benefits of NeuroStar for patients, played a crucial role in boosting system sales. Additionally, the Better Me Guarantee Provider Program, aimed at ensuring timely and consistent patient care, showed promising results with increased patient awareness and follow-up rates.

Neuronetics also discussed operational updates, including the launch of the second phase of the program and plans for further expansion. The company’s continued efforts to expand the labeling for NeuroStar and improve patient outcomes were highlighted as key priorities for the future.

Looking ahead, Neuronetics remains optimistic about its growth prospects, with a strong focus on enhancing patient care standards and expanding access to transformative mental health treatments. The company’s commitment to driving innovation and delivering value to customers and patients was evident throughout the call.

In conclusion, Neuronetics’ recent performance and strategic initiatives position the company for continued success in the evolving landscape of mental health treatments. As they navigate the challenges and opportunities ahead, Neuronetics remains dedicated to driving positive impact and growth in the industry.